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Short-chain sphingolipids, such as C8-Glucosylceramide
(C8-GC) have been described to enhance the cellular
uptake of amphiphilic drugs, in free form or when co-
formulated in liposomes (1,2). The involved mechanism
is currently unknown, but is hypothesized to induce
domain or pore formation in the plasma membrane (3).
The aim of this study is to further explore this specific
drug uptake process by C8-GC to enhance intracellular
delivery of liposomal doxorubicin.
Liposomes, containing different percentages of incor-
porated C8-GC were prepared and loaded with doxoru-
bicin. Characterization was performed by measuring
size, polydispersity index (pdi), phospholipid and doxor-
ubicin content. In vitro anti-tumor activity was studied
towards a panel of human tumor cell lines and normal
cells: endothelial cells and fibroblasts.
Doxorubicin liposomes (Dox-L) enriched with 10 mol%
C8-GC presented less fluctuation in size and pdi than 15
mol% and efficiently retained their contents under culture
conditions (10% serum). In all tumor cell lines tested C8-
GC-Dox-L exerted increased cytotoxicity, resulting in up
to 20 fold lower IC50 values compared to standard Dox-L.
This effect was not observed with endothelial cells and
with fibroblasts it was much less pronounced.
In conclusion, 10 mol% C8-GC-enriched Dox-L had
optimal stability and showed enhanced cytotoxicity
towards tumor cells and not towards normal cells.
Based on these findings, modification of Dox-L
formulations with 10 mol% of C8-GC can be used to
improve drug delivery to tumor cells.
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